tirzepatide 60 units Pen mg Support your weight-management journey with an advanced option designed for real results. Tirzepatide features a dual GLP-1/GIP receptor action, helping with appetite control, increased satiety, and metabolic support Tirzepatide, Compounded 60 mg/vial |

Proposed mechanisms of GLP-1RA-induced acute pancreatitis include pancreatic duct gland hyperplasia, pancreatic ductal obstruction leading to proinflammatory reactions, acinar cell hypertrophy, and pancreatic vascular injury.36 Additionally, another mechanism seen with the use of these drugs could be the increased risk of gallbladder or biliary diseases, especially when used in higher doses, for longer periods of time, and for weight loss.37 Previous animal studies suggested a risk of acute pancreatitis after GLP-1RA-based treatment.38 In addition, an initial analysis of the Food and Drug Administration's (FDA) adverse event reporting databases suggested an increased risk for acute pancreatitis with GLP-1RA-based therapy.39 It is important to note that this type of data analysis may not be the ideal method for comparing adverse event rates between medications

This is a very common and easy-to-work-with concentration

If the current dose is well tolerated but clinical goals are not yet met, the provider may advance per the label

Reference Wen J, Razick A, HowVolkman C, Bernstein E, Nadora D, Truong A, Razick D, Akhtar M, Karabala M, Frezza E

Available at: Accessed 24 March 2022